Neil Gregory Almstead - 07 Jan 2022 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
Chief Technical Ops Officer
Signature
/s/ Avraham S. Adler, attorney-in-fact
Issuer symbol
PTCT
Transactions as of
07 Jan 2022
Net transactions value
-$30,859
Form type
4
Filing time
11 Jan 2022, 15:20:54 UTC
Previous filing
06 Jan 2022
Next filing
27 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Sale $29,125 -756 -2.1% $38.52 35,058 07 Jan 2022 Direct F1
transaction PTCT Common Stock Award $0 +14,400 +41% $0.000000 49,458 07 Jan 2022 Direct F2
transaction PTCT Common Stock Sale $1,734 -45 -2.6% $38.52 1,710 07 Jan 2022 By Spouse F3
transaction PTCT Common Stock Award $0 +780 +46% $0.000000 2,490 07 Jan 2022 By Spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Award $0 +54,000 $0.000000 54,000 07 Jan 2022 Common Stock 54,000 $38.10 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs.
F2 Restricted stock units granted on January 7, 2022 that vest in four equal installments over four years, commencing on January 7, 2023.
F3 Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 150 RSUs from a January 6, 2021 grant of 600 RSUs.
F4 This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.